The Rheumatology Network gout clinical focus page provides information on the latest gout news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for gout drugs.
November 04, 2021
Investigators analyzed comorbidities, such as diabetes, which has been historically associated with gout, to determine what role, if any, they played in increasing the risk of lower extremity amputation.
November 03, 2021
Aaron Broadwell, MD, discusses his upcoming ACR study entitled, “Concomitant immunomodulation and pegloticase therapy: experiences with a variety of immunomodulatory agents in two community rheumatology practices.”
October 01, 2021
Sarah Stewart, PhD, discusses her study entitled "What Represents Treatment Efficacy in Long-term Studies of Gout Flare Prevention? An Interview Study of People With Gout."
September 16, 2021
Hyperuricemia is associated with vascular, cardiac, and renal disease, as well as gout. However, the reliability of a single measurement in defining hyperuricemia is unclear.
September 10, 2021
“There is likely to be a bidirectional relationship between sleep and gout, as gout flares may be influenced by circadian rhythms, and sleep quality is likely to be influenced by gout flares,” investigators explained. “Given the morbidity associated with sleep problems, we should be vigilant regarding sleep health in our patients with gout.”
August 18, 2021
The stigma surrounding gout has contributed to the general unease patients have about their condition.
August 11, 2021
Brian LaMoreaux, MD, MS, discusses the recent study entitled, "Improving outcomes for patients hospitalised with gout: a systematic review."
June 02, 2021
As a part of our EULAR 2021 coverage, Rheumatology Network sat down with John Botson, MD, RPh, CCD, to discuss why patients with uncontrolled gout are significantly burdened with systemic co-morbid disease, why gout is more prevalent and severe in patients who have received kidney transplants, and why such few studies have been published on the use of pegloticase in organ transplant patients.
May 25, 2021
Rheumatology Network interviewed Puja Khanna, MD, MPH, Associate Professor of Medicine from the University of Michigan, about her study that evaluated how patients with poorly controlled gout fared when they were treated with pegloticase and mycophenolate mofetil combination therapy.
May 20, 2021
Patients with gout maintained therapeutic response at 6 months when treated with a combination of methotrexate (MTX) and pegloticase, as opposed to pegloticase therapy alone.